Bluebird Bio Inc., of Cambridge, Mass., reported data at the Cooley's Anemia Foundation Symposium in Chicago, including an update from one subject with beta-thalassemia major treated in 2007 in the LG001 study using the firm's first-generation HPV569 lentiviral vector.